Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Merrimack Pharmaceuticals, Inc. MACK
$12.47
-$0.06 (-0.48%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
188327498.00000000
-
week52high
13.66
-
week52low
3.00
-
Revenue
-445000
-
P/E TTM
-123
-
Beta
1.80311400
-
EPS
-0.11000000
-
Last Dividend
10.29755100
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Baird | Neutral | Neutral | 22 окт 2018 г. |
| Baird | Neutral | Neutral | 26 июн 2018 г. |
| JP Morgan | Underweight | Neutral | 25 июн 2018 г. |
| JP Morgan | Neutral | Overweight | 07 окт 2016 г. |
| BTIG Research | Neutral | Neutral | 19 авг 2016 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Andersen Eric | A | 324306 | 450 | 31 янв 2023 г. |
| Andersen Eric | A | 1284635 | 1782 | 31 янв 2023 г. |
| Andersen Eric | A | 323856 | 4958 | 30 янв 2023 г. |
| Andersen Eric | A | 1282853 | 19750 | 30 янв 2023 г. |
| Andersen Eric | A | 318898 | 4410 | 27 янв 2023 г. |
| Andersen Eric | A | 1263103 | 17465 | 27 янв 2023 г. |
| Levy Noah G. | A | 1119586 | 100000 | 12 янв 2023 г. |
| Radeljevic Ana | A | 4156 | 4156 | 06 янв 2023 г. |
| Levy Noah G. | A | 1019586 | 5300 | 03 янв 2023 г. |
| Andersen Eric | A | 314488 | 8219 | 03 янв 2023 г. |
Новостная лента
Merrimack Still Has Significant Arbitrage Potential
Seeking Alpha
04 янв 2023 г. в 10:33
In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share.
Merrimack Pharmaceuticals (MACK) Stock Skyrockets Over 240%: Details
Pulse2
09 ноя 2022 г. в 13:12
The stock price of Merrimack Pharmaceuticals (MACK) skyrocketed by over 240% today. This is why.
Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment
Market Watch
09 ноя 2022 г. в 10:13
Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% IPN, +3.85% said overnight that its Onivyde pancreatic cancer treatment met the primary endpoint of a Phase 3 trial. Ipsen said it plans to file a supplemental New Drug Application (NDA) with the U.S. Food and Drug Administration for Onivyde.
Return Of The Mack: A Deeply Misunderstood Near-Term Readout
Seeking Alpha
31 окт 2022 г. в 09:00
MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cancer drugs are targeted therapies that fail in the clinic.